These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Chemotherapy of cancer of the breast in the metastatic phase].
    Author: Clavel M, Biron P, Chauvin F, Guastalla JP, Rebattu P, el Foudeh M.
    Journal: Bull Cancer; 1989; 76(1):75-85. PubMed ID: 2653473.
    Abstract:
    Metastatic breast adenocarcinoma is a very chemosensitive tumor. Polychemotherapy (CT) is more active than mono-CT inducing a 50-60% response rate in naive chemotherapy patients. The response rate is increased by adding hormonotherapy (HT) to CT in hormone-receptors positive patients. Whether or not HT and CT should be concomitant or consecutive is still questionable. The overall survival remains poor (22-30 months) and no improvement happened during the last decades. A hope for the future is possible from 2 different concepts: high dose chemotherapy or intermittent CT with successive short inductions treatment and no maintenance therapy.
    [Abstract] [Full Text] [Related] [New Search]